Affinity Asset Advisors LLC Makes New $1.24 Million Investment in OnKure Therapeutics (NASDAQ:OKUR)

Affinity Asset Advisors LLC bought a new position in shares of OnKure Therapeutics (NASDAQ:OKUR) during the 4th quarter, HoldingsChannel.com reports. The fund bought 144,159 shares of the company’s stock, valued at approximately $1,240,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of OKUR. Highbridge Capital Management LLC bought a new stake in OnKure Therapeutics during the fourth quarter worth $3,438,000. Geode Capital Management LLC bought a new stake in shares of OnKure Therapeutics during the 4th quarter worth $659,000. Aisling Capital Management LP bought a new stake in shares of OnKure Therapeutics during the 4th quarter worth $762,000. Aldebaran Capital LLC purchased a new position in shares of OnKure Therapeutics in the 4th quarter worth about $392,000. Finally, Renaissance Technologies LLC purchased a new stake in OnKure Therapeutics during the fourth quarter worth about $408,000. Hedge funds and other institutional investors own 90.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on OKUR shares. Oppenheimer decreased their price target on shares of OnKure Therapeutics from $35.00 to $30.00 and set an “outperform” rating for the company in a research note on Tuesday, March 11th. HC Wainwright decreased their target price on OnKure Therapeutics from $40.00 to $34.00 and set a “buy” rating for the company in a research report on Tuesday, March 18th. Three analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $32.33.

OnKure Therapeutics Trading Up 3.1 %

NASDAQ OKUR opened at $3.04 on Tuesday. The company has a market capitalization of $40.85 million, a price-to-earnings ratio of -0.25 and a beta of 0.35. The company has a 50 day simple moving average of $4.69. OnKure Therapeutics has a 12-month low of $2.57 and a 12-month high of $20.00.

OnKure Therapeutics (NASDAQ:OKUR) last issued its earnings results on Monday, March 10th. The company reported ($1.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.51). As a group, equities research analysts expect that OnKure Therapeutics will post -4.05 earnings per share for the current fiscal year.

OnKure Therapeutics Profile

OnKure Therapeutics, Inc engages in discovering and developing precision medicines that target biologically validated drivers of cancers underserved by available therapies. The company uses a structure and computational chemistry driven drug design platform, committed to improving clinical outcomes for patients by building a robust pipeline of small molecule drugs designed to selectively target specific mutations thought to be key drivers of cancer.